BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Luxenburger H, Neumann-Haefelin C, Thimme R, Boettler T. HCV-Specific T Cell Responses During and After Chronic HCV Infection. Viruses 2018;10:E645. [PMID: 30453612 DOI: 10.3390/v10110645] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 Goto K, Roca Suarez AA, Wrensch F, Baumert TF, Lupberger J. Hepatitis C Virus and Hepatocellular Carcinoma: When the Host Loses Its Grip. Int J Mol Sci. 2020;21. [PMID: 32357520 DOI: 10.3390/ijms21093057] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
2 Thimme R. T cell immunity to hepatitis C virus: Lessons for a prophylactic vaccine. J Hepatol 2021;74:220-9. [PMID: 33002569 DOI: 10.1016/j.jhep.2020.09.022] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
3 Weigand K, Peschel G, Grimm J, Luu K, Schacherer D, Wiest R, Müller M, Schwarz H, Buechler C. Soluble CD137 is a novel serum marker of liver cirrhosis in patients with hepatitis C and alcohol-associated disease etiology. Eur J Immunol 2021. [PMID: 34914098 DOI: 10.1002/eji.202149488] [Reference Citation Analysis]
4 Echeverría N, Comas V, Aldunate F, Perbolianachis P, Moreno P, Cristina J. In the era of rapid mRNA-based vaccines: Why is there no effective hepatitis C virus vaccine yet? . World J Hepatol 2021; 13(10): 1234-1268 [PMID: 34786164 DOI: 10.4254/wjh.v13.i10.1234] [Reference Citation Analysis]
5 Osuch S, Metzner KJ, Caraballo Cortés K. Reversal of T Cell Exhaustion in Chronic HCV Infection. Viruses 2020;12:E799. [PMID: 32722372 DOI: 10.3390/v12080799] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Hlady RA, Zhao X, El Khoury LY, Luna A, Pham K, Wu Q, Lee JH, Pyrsopoulos NT, Liu C, Robertson KD. Interferon drives HCV scarring of the epigenome and creates targetable vulnerabilities following viral clearance. Hepatology 2022;75:983-96. [PMID: 34387871 DOI: 10.1002/hep.32111] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
7 Wildner NH, Walker A, Brauneck F, Ditt V, Peine S, Huber S, Haag F, Beisel C, Timm J, Schulze zur Wiesch J. Transcriptional Pattern Analysis of Virus-Specific CD8+ T Cells in Hepatitis C Infection: Increased Expression of TOX and Eomesodermin During and After Persistent Antigen Recognition. Front Immunol 2022;13:886646. [DOI: 10.3389/fimmu.2022.886646] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Wolski D, Lauer GM. Hepatitis C Virus as a Unique Human Model Disease to Define Differences in the Transcriptional Landscape of T Cells in Acute versus Chronic Infection. Viruses 2019;11:E683. [PMID: 31357397 DOI: 10.3390/v11080683] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
9 Leslie J, Geh D, Elsharkawy AM, Mann DA, Vacca M. Metabolic dysfunction and cancer in HCV: shared pathways and mutual interactions. Journal of Hepatology 2022. [DOI: 10.1016/j.jhep.2022.01.029] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Fukuda R, Sugawara S, Kondo Y. Immune Checkpoint Inhibitor Can Reduce HCV-RNA without Liver Damage. Intern Med 2020;59:2245-8. [PMID: 32522918 DOI: 10.2169/internalmedicine.3726-19] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
11 Hamley IW. Peptides for Vaccine Development. ACS Appl Bio Mater 2022. [PMID: 35195008 DOI: 10.1021/acsabm.1c01238] [Reference Citation Analysis]
12 Abouelasrar Salama S, Lavie M, De Buck M, Van Damme J, Struyf S. Cytokines and serum amyloid A in the pathogenesis of hepatitis C virus infection. Cytokine Growth Factor Rev 2019;50:29-42. [PMID: 31718982 DOI: 10.1016/j.cytogfr.2019.10.006] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
13 Rees-spear C, Mccoy LE. Vaccine responses in ageing and chronic viral infection. Oxford Open Immunology 2021;2:iqab007. [DOI: 10.1093/oxfimm/iqab007] [Reference Citation Analysis]
14 Llorens-Revull M, Costafreda MI, Rico A, Guerrero-Murillo M, Soria ME, Píriz-Ruzo S, Vargas-Accarino E, Gabriel-Medina P, Rodríguez-Frías F, Riveiro-Barciela M, Perales C, Quer J, Sauleda S, Esteban JI, Bes M. Partial restoration of immune response in Hepatitis C patients after viral clearance by direct-acting antiviral therapy. PLoS One 2021;16:e0254243. [PMID: 34242330 DOI: 10.1371/journal.pone.0254243] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Zoldan K, Ehrlich S, Killmer S, Wild K, Smits M, Russ M, Globig AM, Hofmann M, Thimme R, Boettler T. Th1-Biased Hepatitis C Virus-Specific Follicular T Helper-Like Cells Effectively Support B Cells After Antiviral Therapy. Front Immunol 2021;12:742061. [PMID: 34659236 DOI: 10.3389/fimmu.2021.742061] [Reference Citation Analysis]
16 Han JW, Sung PS, Kim KH, Hong SH, Shin EC, Jun Song M, Park SH. Dynamic Changes in Ex Vivo T-Cell Function After Viral Clearance in Chronic HCV Infection. J Infect Dis 2019;220:1290-301. [PMID: 31152667 DOI: 10.1093/infdis/jiz291] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
17 Passaes C, Millet A, Madelain V, Monceaux V, David A, Versmisse P, Sylla N, Gostick E, Llewellyn-Lacey S, Price DA, Blancher A, Dereuddre-Bosquet N, Desjardins D, Pancino G, Le Grand R, Lambotte O, Müller-Trutwin M, Rouzioux C, Guedj J, Avettand-Fenoel V, Vaslin B, Sáez-Cirión A. Optimal Maturation of the SIV-Specific CD8+ T Cell Response after Primary Infection Is Associated with Natural Control of SIV: ANRS SIC Study. Cell Rep 2020;32:108174. [PMID: 32966788 DOI: 10.1016/j.celrep.2020.108174] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
18 Khanam A, Kottilil S, Wilson E. Reconstitution of T follicular helper-humoral immune axis with elimination of hepatitis C virus. Sci Rep 2020;10:19924. [PMID: 33199783 DOI: 10.1038/s41598-020-77020-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
19 Smith S, Honegger JR, Walker C. T-Cell Immunity against the Hepatitis C Virus: A Persistent Research Priority in an Era of Highly Effective Therapy. Cold Spring Harb Perspect Med 2021;11:a036954. [PMID: 32205413 DOI: 10.1101/cshperspect.a036954] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
20 Schank M, Zhao J, Wang L, Nguyen LNT, Cao D, Dang X, Khanal S, Zhang J, Zhang Y, Wu XY, Ning S, Gazzar ME, Moorman JP, Yao ZQ. Oxidative Stress Induces Mitochondrial Compromise in CD4 T Cells From Chronically HCV-Infected Individuals. Front Immunol 2021;12:760707. [PMID: 34956192 DOI: 10.3389/fimmu.2021.760707] [Reference Citation Analysis]
21 Baumert TF, Hoshida Y. Addressing the Challenges of Hepatitis C Cure and Persistent Risk of Hepatocellular Carcinoma. Viruses 2019;11:E441. [PMID: 31096600 DOI: 10.3390/v11050441] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
22 Marín MQ, Sliepen K, García-Arriaza J, Koekkoek SM, Pérez P, Sorzano CÓS, Gómez CE, Sanders RW, Esteban M. Optimized Hepatitis C Virus (HCV) E2 Glycoproteins and their Immunogenicity in Combination with MVA-HCV. Vaccines (Basel) 2020;8:E440. [PMID: 32764419 DOI: 10.3390/vaccines8030440] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
23 Perpiñán E, Pérez-Del-Pulgar S, Londoño MC, Mariño Z, Lens S, Leonel T, Bartres C, García-López M, Rodriguez-Tajes S, Forns X, Koutsoudakis G. Chronic genotype 1 hepatitis C along with cirrhosis drives a persistent imprint in virus-specific CD8+ T cells after direct-acting antiviral therapies. J Viral Hepat 2020;27:1408-18. [PMID: 32812325 DOI: 10.1111/jvh.13370] [Reference Citation Analysis]
24 Torres-vázquez B, María de Lucas A, García-crespo C, Antonio García-martín J, Fragoso A, Fernández-algar M, Perales C, Domingo E, Moreno M, Briones C. In vitro selection of high affinity DNA and RNA aptamers that detect hepatitis C virus core protein of genotypes 1 to 4 and inhibit virus production in cell culture. Journal of Molecular Biology 2022. [DOI: 10.1016/j.jmb.2022.167501] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Matic S, Popovic S, Baskic D, Todorovic D, Vukovic N, Stankovic M, Djurdjevic P, Zdravkovic N, Mijailovic Z. Methanolic Extract of Teucrium Polium Exerts Immunomodulatory Properties in Human Peripheral Blood Mononuclear Cells. Serbian Journal of Experimental and Clinical Research 2020;0:000010247820200018. [DOI: 10.2478/sjecr-2020-0018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Yeh ML, Huang CF, Huang CI, Holmes JA, Hsieh MH, Tsai YS, Liang PC, Tsai PC, Hsieh MY, Lin ZY, Chen SC, Huang JF, Dai CY, Chuang WL, Chung RT, Yu ML. Hepatitis B-related outcomes following direct-acting antiviral therapy in Taiwanese patients with chronic HBV/HCV co-infection. J Hepatol 2020;73:62-71. [PMID: 32061869 DOI: 10.1016/j.jhep.2020.01.027] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 13.5] [Reference Citation Analysis]
27 Malonis RJ, Lai JR, Vergnolle O. Peptide-Based Vaccines: Current Progress and Future Challenges. Chem Rev 2020;120:3210-29. [PMID: 31804810 DOI: 10.1021/acs.chemrev.9b00472] [Cited by in Crossref: 84] [Cited by in F6Publishing: 66] [Article Influence: 28.0] [Reference Citation Analysis]